SCHEMBL1269795

SCHEMBL1269795

Nc1cc(C(=O)O)[nH]n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14397160 0.83 HCAR3 (0.47)
SCHEMBL28856288 0.82
SCHEMBL17641610 0.80
SCHEMBL26043543 0.77 KDM5A (0.37)
SCHEMBL10663393 0.77 KDM5A (0.37)
SCHEMBL10663399 0.77 KDM5A (0.37)
SCHEMBL19303858 0.75 ALDH1A1 (0.39)
SCHEMBL1662796 0.75 CHEK1 (0.56)
SCHEMBL286531 0.75 MAPK1 (0.65)
SCHEMBL70577 0.74 HCAR2 (0.59)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011147797-A2 HYBRID COMPOUND, THE USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF Forschungszentrum Jülich GmbH (DE) 2011-12-01 WO claimed
US-12617797-B2 Substituted pyrazolo [1,5-a]pyrimidines having multimodal activity against pain ESTEVE PHARMACEUTICALS, S.A. (ES) 2026-05-05 US disclosed
US-20240059690-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2024-02-22 US disclosed
EP-3747454-B9 AMYLOID-BETA BINDING PEPTIDES AND THESE PEPTIDES FOR USE IN THE THERAPY AND DIAGNOSIS OF ALZHEIMER'S DEMENTIA PRIAVOID GMBH (DE) 2023-10-04 EP disclosed
EP-3747454-B1 AMYLOID-BETA BINDING PEPTIDES AND THESE PEPTIDES FOR USE IN THE THERAPY AND DIAGNOSIS OF ALZHEIMER'S DEMENTIA PRIAVOID GMBH (DE) 2023-06-07 EP disclosed
EP-4157843-A1 PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2023-04-05 EP disclosed
CN-115698008-A Pyrazolo [1,5-a ] pyrimidine derivatives having multimodal activity against pain 埃斯特韦制药股份公司 2023-02-03 CN disclosed
EP-3346273-B1 NOVEL D-ENANTIOMERIC PEPTIDES DERIVED FROM D3 AND THEIR USE PRIAVOID GMBH (DE) 2023-01-04 EP disclosed
EP-3260865-B1 METHOD FOR THE TREATMENT OF BLOOD, BLOOD PRODUCTS AND ORGANS PRIAVOID GMBH (DE) 2022-12-28 EP disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-20090239838-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-09-24 US disclosed
US-20090239838-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-09-24 US disclosed
CN-101511835-A Pyrrolotriazine kinase inhibitors BRISTOL MYERS SQUIBB CO (US) 2009-08-19 CN disclosed
US-7534792-B2 e.g. 1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-methylpyrrolidine-2-carboxamide; tyrosine kinase inhibitor; anticarcinogenic, antiproliferative agent, neurodegenerative diseases; Alzheimer's disease BRISTOL-MYERS SQUIBB COMPANY (US) 2009-05-19 US disclosed
US-7534792-B2 e.g. 1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-methylpyrrolidine-2-carboxamide; tyrosine kinase inhibitor; anticarcinogenic, antiproliferative agent, neurodegenerative diseases; Alzheimer's disease BRISTOL-MYERS SQUIBB COMPANY (US) 2009-05-19 US disclosed
US-20080009497-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-01-10 US disclosed
US-20080009497-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-01-10 US disclosed
US-20050239808-A1 Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH (DE) 2005-10-27 US disclosed
EP-1503990-A1 ACTIVE SUBSTANCES FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF DISEASES IN WHICH ABNORMAL PROTEIN STRUCTURES OCCUR Transmit Gesellschaft für Technologietransfer mbH (DE) 2005-02-09 EP disclosed
WO-2003095429-A1 ACTIVE SUBSTANCES FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF DISEASES IN WHICH ABNORMAL PROTEIN STRUCTURES OCCUR TransMIT Gesellschaft für Technologietransfer mbH (DE) 2003-11-20 WO disclosed